Varian has announced that its Halcyon system has received Taiwan FDA approval, which allows the company to market this new cancer treatment system in Taiwan. This approval further expands the global availability of Halcyon and high-quality, cost-effective cancer treatments.
“As an advanced cancer treatment system with a human-centered and user-friendly design, Halcyon is engineered to revolutionize clinical workflow, accelerate installation timeframes, expedite commissioning, simplify training and automate treatment,” according to a news release. “It simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT). It is well suited to handle the majority of cancer patients, offering advanced treatments for lung, esophagus, brain, head and neck, and many other forms of cancer.”
“We are very proud to further expand Halcyon’s global availability, and with Taiwan FDA approval, clinicians in Taiwan now can take advantage of the unique capabilities of this system,” said Kevin O’Reilly, president of Asia Pacific for Varian. “We look forward to further growing Halcyon’s availability as we partner with our customers in the fight against cancer.”
Halcyon has already received FDA 510(k) clearance in the U.S., CE mark in Europe, Shonin approval in Japan and ANVISA registration in Brazil since its launch in May 2017.